Enhancing the therapeutic potential of curcumin: a novel nanoformulation for targeted anticancer therapy to colorectal cancer with reduced miR20a and miR21 expression
Biomedical Materials (Bristol), ISSN: 1748-605X, Vol: 19, Issue: 2
2024
- 2Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Captures2
- Readers2
Article Description
Curcumin (Cur) possesses remarkable pharmacological properties, including cardioprotective, neuroprotective, antimicrobial, and anticancer activities. However, the utilization of Cur in pharmaceuticals faces constraints owing to its inadequate water solubility and limited bioavailability. To overcome these hurdles, there has been notable focus on exploring innovative formulations, with nanobiotechnology emerging as a promising avenue to enhance the therapeutic effectiveness of these complex compounds. We report a novel safe, effective method for improving the incorporation of anticancer curcumin to induce apoptosis by reducing the expression levels of miR20a and miR21. The established method features three aspects that, to our knowledge, have not been formally verified: (1) use of a novel formula to incorporate curcumin, (2) use of all biocompatible biodegradable materials to produce this formula without leaving harmful residues, and (3) an incorporation process at temperatures of approximately 50 °C. The formula was prepared from lecithin (LE), and chitosan (CH) with an eco-friendly emulsifying agent and olive oil as the curcumin solvent. The formula was converted to nanoscale through ultrasonication and probe sonication at a frequency of 20 kHz. Transmission electron microscopy showed that the nano formula was spherical in shape with sizes ranging between 49.7 nm in diameter and negative zeta potentials ranging from 28 to 34 mV. Primers miR20a and miR21 were designed for molecular studies. Nearly complete curcumin with an encapsulation efficiency of 91.1% was established using a straight-line equation. The nano formula incorporated with curcumin was used to prepare formulations that exhibited anticancer activities. The apoptosis pathway in cancer cells was activated by the minimum inhibitory concentration of the nano formula. These findings suggest the potential of this nanoformulation as an effective and selective cancer treatment that does not affect the normal cells.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85183462010&origin=inward; http://dx.doi.org/10.1088/1748-605x/ad1dfc; http://www.ncbi.nlm.nih.gov/pubmed/38215475; https://iopscience.iop.org/article/10.1088/1748-605X/ad1dfc; https://dx.doi.org/10.1088/1748-605x/ad1dfc; https://validate.perfdrive.com/9730847aceed30627ebd520e46ee70b2/?ssa=1f5776aa-f20c-427a-bd9f-0445c44246bf&ssb=32193298815&ssc=https%3A%2F%2Fiopscience.iop.org%2Farticle%2F10.1088%2F1748-605X%2Fad1dfc&ssi=3ab4c52a-cnvj-4916-aaac-d16476d9f7bb&ssk=botmanager_support@radware.com&ssm=886985598584506368924487562720556&ssn=0368b80b3e46d87da847f6d9f9cf29f0e2b36db1c10c-a37a-41b2-bbdf8d&sso=5f649205-c45fe023bb49bddbb49c655fceb0bf8ed2fe72f0572a9433&ssp=94722956111723799260172386852091392&ssq=85111281805720844456431741915749270194261&ssr=MzQuMjM2LjI2LjMx&sst=com.plumanalytics&ssu=&ssv=&ssw=&ssx=eyJ1em14IjoiN2Y5MDAwYTI1MzhkOWUtZTQwNC00NDUyLTgxNjQtYzRmNzFjNGE4OTRmMi0xNzIzNzMxNzQxMjU1ODYzMTY2NjktNjU2MjUxNDI3ZjgwN2Y2ZDg5MiIsInJkIjoiaW9wLm9yZyIsIl9fdXptZiI6IjdmNjAwMDU2NDIwN2VjLWJmZTAtNDMzZS1iNDU4LWFiMzUxNDRjNzEwNzE3MjM3MzE3NDEyNTU4NjMxNjY2OS1mMGY1OGMwNjAyOWMwZWYzODkyIn0=
IOP Publishing
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know